Skip to main content
Cyber Week Sale - Get 40% off Vantage
Get Started
SubscribeLogin
Published • loading... • Updated

TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet

  • TransThera Sciences Inc. announced that clinical results from a Phase 2 trial of tinengotinib were published in The Lancet Gastroenterology and Hepatology.
  • The trial involved patients with FGFR2 fusion-positive Cholangiocarcinoma who had resistance to prior FGFR inhibitor therapy.
  • Tinengotinib showed clinical activity and durable responses in patients with FGFR2 fusion-positive Cholangiocarcinoma.
  • This study offers insights into treatment strategies for patients with FGFR-altered Cholangiocarcinoma.
Insights by Ground AI

36 Articles

WRICWRIC
+35 Reposted by 35 other sources
Center

TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet

·Richmond, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 55% of the sources are Center
55% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

WRIC broke the news in Richmond, United States on Thursday, December 4, 2025.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Gaithersburg icon

Gaithersburg

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal